Uncategorised - European Medical Journal

Brain Scan Links Dopamine Changes To Psychosis Across Mood Disorders

Dopamine changes link to psychotic symptoms, suggesting new treatment avenues for mood disorders with psychosis.

Novel Bispecific Antibody Shows Promise Against Aggressive Blood Cancers

A new bispecific antibody therapy, AFM28, has shown strong preclinical results in targeting treatment-resistant cells in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), according to new research.

Intermittent Fasting Might Improve Symptoms of Long COVID-19

Intermittent fasting decreased symptoms of long COVID-19 in a randomised crossover trial that compared the efficacy and safety of 4 weeks of 1–2-day fasting plus a restricted diet versus 4 weeks of mild time-restricted eating and a restricted diet

Get to Know Tau and its role in Alzheimer's Disease

Suzanne Schindler provides her perspectives from Clinical Trials on Alzheimer’s Disease (CTAD) 2024 on plasma tau biomarkers, covering…

Current Trends of Methotrexate Therapy

Explore Methotrexate (MTX) in rheumatoid arthritis care, including its benefits, COVID-19 learnings, and the latest evidence on MTX-associated fibrotic interstitial lung disease.

Nanomedicine Breakthrough Improves Drug Delivery in Pediatric Brain Tumors

Pediatric central nervous system (CNS) tumors remain among the most fatal childhood cancers, largely because the blood-brain barrier (BBB) restricts effective therapeutic delivery and worsens clinical outcomes.

Targeted Therapies Offer Hope in Inflammatory Myopathies

Idiopathic inflammatory myopathies are complex immune-mediated disorders with multisystem involvement, and recent advances are reshaping both classification and treatment approaches.

Illustration of scientific tools

Novartis to tackle rare disease diagnosis with AI

Novartis is partnering with Atropos Health to develop AI models that accelerate rare disease diagnosis, starting with a rare blood disorder.

Elexacaftor-Tezacaftor-Ivacaftor Cuts Liver Complications in Cystic Fibrosis

The availability of elexacaftor–tezacaftor–ivacaftor (ETI) has been associated with a marked reduction in cystic fibrosis liver disease (CFLD) progression, according to a nationwide analysis.

Novel Combination Therapy Shows Rapid Improvement in Liver Health in Patients with MASLD

Silymarin, vitamin E, and phospholipids combination therapy effectively reduces liver steatosis, fibrosis, and metabolic risk in MASLD.